Stage (next event)
Phase 2 (Data)
Catalyst Info & Data Links
TITLE: PTG-200 (IL-23R Antagonist) for Crohn's Disease - Phase 2 Data
ClinicalTrials.gov (NCT04102111): A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease (PRISM)
WHAT IS THE CATALYST EVENT?
Phase 2 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Mechanism of Action
MECHANISM OF ACTION
PTG-200 is an oral peptide interleukin-23 receptor (IL-23R) antagonist being co-developed with Janssen, for the treatment of inflammatory bowel disease and is initially in development for the treatment of patients with Crohn's disease. PTG-200 is designed to offer choices to patients in addition to injectable antibody therapeutics that target the IL-23 pathway, including the potential for improved safety and tolerability and better compliance compared to therapeutics administered by injection.
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post